

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/253154 A1

(43) International Publication Date
08 December 2022 (08.12.2022)

(51) International Patent Classification:

C07K 16/30 (2006.01) *C12N 15/85* (2006.01)
C07K 16/46 (2006.01) *A61K 47/68* (2017.01)
C12N 15/13 (2006.01) *A61K 39/395* (2006.01)
C12N 15/62 (2006.01) *A61K 39/00* (2006.01)
C12N 15/64 (2006.01) *A61P 35/00* (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2022/095839

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

30 May 2022 (30.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/097239
31 May 2021 (31.05.2021) CN
PCT/CN2021/097240
31 May 2021 (31.05.2021) CN
PCT/CN2021/106783
16 July 2021 (16.07.2021) CN
PCT/CN2021/106784
16 July 2021 (16.07.2021) CN

(71) Applicant: **SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.** [CN/CN]; No.238, Tianshan Street Hi-Tech. Development District, Shijiazhuang, Hebei 050035 (CN).

(72) Inventor: **JIA, Zhenhua**; No.238, Tianshan Street Hi-Tech. Development District, Shijiazhuang, Hebei 050035 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3 FL, Building 2, Yard 3, FengXiuZhongLu Road, Haidian District, Beijing 100094 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: MONOCLONAL ANTIBODIES AGAINST CLDN18.2 AND FC-ENGINEERED VERSIONS THEREOF

(57) Abstract: Provided is a panel of monoclonal antibodies which specifically bind to CLDN18.2 and do not specifically bind to CLDN18.1, and optionally have an engineered Fc region.

WO 2022/253154 A1